Long Read Sequencing Key Players | Innovation and Product Evolution | Market Entry and Expansion Strategies | Investment and Capital Allocation | Technology Commercialization | Market Trends Analysis | Future Market Positioning

Long Read Sequencing Companies and Competitive Landscape

The long read sequencing market was estimated at US$ 0.6 billion in 2023 and is projected to grow to US$ 11.6 billion by 2034, rising at a compound annual growth rate (CAGR) of 30.96% from 2024 to 2034.

Top Companies in the Long Read Sequencing:

• 10x Genomics
• Agilant Technologies
• Azenta Life Sciences
• BGI Genomics
• Element Biosciences
• Illumina
• MGI
• Oxford Nanopore Technologies
• Pacific Biosciences (PacBio)
• Qiagen
• Quantapore, Inc.
• Thermo Fisher Scientific
• Universal Sequencing Technology Corporation

Latest Announcements by Industry Leaders

In January 2024, PacBio CEO Christian Henry announced that it more than doubled its fourth-quarter sales of $58.4 million, i.e., a 113% increase compared to $27.4 million collected in the last three months of 2022. This surge in revenue was attributed to the recently launched two major DNA sequencing machines. He also said that he expects to see long-read DNA sequencing take as much as half of the market within the next five years.

Recent Developments in the Long Read Sequencing Market

• In October 2024, PacBio announced a novel and improved long-read sequencing chemistry, SPRQ, for its Revio sequencing system. The new chemistry reduces DNA input by four-fold, enabling a 33% increase in data output, improving methylation calling, and expanding support for multi-omics.
• In July 2024, researchers from the King Abdullah University of Science and Technology developed a novel long-read sequencing platform, NanoRanger, that offers an accurate, rapid, and low-cost method for diagnosing Mendelian genetic disorders within just a few hours.

If you have any questions, please feel free to contact us at sales@towardshealthcare.com